Biogen Inc.
BIIB
$181.62
$0.870.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.77% | 3.36% | 1.59% | -1.62% | -3.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.77% | 3.36% | 1.59% | -1.62% | -3.86% |
| Cost of Revenue | -1.74% | -1.24% | 14.30% | 3.72% | 7.10% |
| Gross Profit | 7.27% | 5.17% | -2.54% | -3.48% | -7.49% |
| SG&A Expenses | 4.88% | -3.10% | -3.81% | -4.69% | -8.61% |
| Depreciation & Amortization | 38.14% | 52.13% | 56.31% | 60.64% | 60.39% |
| Other Operating Expenses | 10.25% | 11.47% | 8.62% | 16.27% | 25.99% |
| Total Operating Expenses | 1.25% | -2.90% | -6.00% | -10.54% | -10.52% |
| Operating Income | 14.71% | 24.97% | 30.69% | 36.05% | 21.68% |
| Income Before Tax | -0.11% | 36.82% | 32.43% | 46.98% | 18.46% |
| Income Tax Expenses | 1.30% | 70.95% | 75.06% | 102.37% | 98.57% |
| Earnings from Continuing Operations | -0.37% | 32.21% | 26.73% | 40.53% | 10.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 366.67% |
| Net Income | -0.41% | 32.10% | 26.80% | 40.57% | 10.49% |
| EBIT | 14.71% | 24.97% | 30.69% | 36.05% | 21.68% |
| EBITDA | 16.04% | 26.07% | 31.33% | 36.05% | 23.72% |
| EPS Basic | -1.04% | 31.43% | 26.09% | 39.70% | 9.71% |
| Normalized Basic EPS | 17.61% | 23.95% | 25.43% | 24.08% | 6.65% |
| EPS Diluted | -1.01% | 31.58% | 26.31% | 40.06% | 9.99% |
| Normalized Diluted EPS | 17.72% | 24.05% | 25.65% | 24.28% | 6.85% |
| Average Basic Shares Outstanding | 0.60% | 0.60% | 0.60% | 0.59% | 0.59% |
| Average Diluted Shares Outstanding | 0.50% | 0.55% | 0.48% | 0.48% | 0.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |